Holen Sie sich die Stockscreener-App
20.10
0.70%
0.14
Vorhandelsmarkt:
20.10
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-05-05 - Seeking Alpha
HC Wainwright Has Optimistic Outlook of SNDX Q2 Earnings - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - simplywall.st
(SNDX) Risk Channels and Responsive Allocation - Stock Traders Daily
Biotech Momentum Builds As Syndax Pharmaceuticals Draws Market Attention - Kalkine Media
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst Upgrade - MarketBeat
Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook By Investing.com - Investing.com Canada
Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook - Investing.com
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Released Its First-Quarter Earnings: Here's What Analysts Think - 富途牛牛
HC Wainwright Has Optimistic Outlook of SNDX FY2030 Earnings - MarketBeat
MSN Money - MSN
Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives - Sahm
Net current asset value per share of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView
Syndax Pharmaceuticals Q1 Loss Narrows, Revenue Rises - Moomoo
Syndax Pharmaceuticals Reports Over $100 Million in Q1 Combined Sales - HarianBasis.co
Jefferies Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
Syndax Pharmaceuticals 1Q Loss $42.7M >SNDX - Moomoo
Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain TractionWhat’s Really Shifting? - Yahoo Finance
Syndax Pharmaceuticals Inc ($SNDX) CEO 2025 Pay Revealed - Quiver Quantitative
Stifel raises Syndax Pharmaceuticals stock price target on therapy trajectory By Investing.com - Investing.com Canada
Jefferies cuts Syndax Pharmaceuticals price target on transplant impact By Investing.com - Investing.com Canada
SNDX Maintained by Barclays -- Price Target Raised to $37 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 7.1%Time to Sell? - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $37.00 - MarketBeat
Syndax Pharmaceuticals stock price target raised to $29 by BofA - Investing.com Australia
Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highligh - GuruFocus
SNDX SWOT Analysis: Financial Resilience Amidst Clinical Development Challenges Revealed in 10-Q Filing - GuruFocus
Earnings Call Summary | Syndax Pharmaceuticals(SNDX.US) Q1 2026 Earnings Conference - Moomoo
Syndax Pharmaceuticals (SNDX) Reports Strong Q1 2026 Earnings an - GuruFocus
Syndax Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Quarterly Earnings Results - MarketBeat
SNDX Sees Strong Demand Despite Q1 Revenue Miss - GuruFocus
How Should Investors Value Syndax Pharmaceuticals (SNDX) After Q - GuruFocus
Earnings call transcript: Syndax Pharmaceuticals beats Q1 2026 EPS expectations - Investing.com
Earnings Flash (SNDX) Syndax Pharmaceuticals Posts Q1 Loss $0.48, vs. FactSet Est of $0.61 Loss - marketscreener.com
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Syndax (NASDAQ: SNDX) details 2026 virtual meeting, director votes and 7.2M-share plan - Stock Titan
Q1 2026 Syndax Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
SNDX: Revenue up 224% to $64.9M; net loss halved; strong growth in Revuforj and Niktimvo sales - TradingView
Syndax: Q1 Earnings Snapshot - KVUE
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Earnings Flash (SNDX) Syndax Pharmaceuticals, Inc. Reports Q1 Revenue $64.9M, vs. FactSet Est of $69.8M - marketscreener.com
Syndax Pharmaceuticals | 10-Q: Q1 2026 Earnings Report - Moomoo
Syndax Pharmaceuticals Sees 2026 Total R&D Plus SG&A Expenses Approximately $400 M>SNDX - Moomoo
Cancer drug sales top $100M as Syndax lines up late-2026 trial data - Stock Titan
Syndax (NASDAQ: SNDX) triples revenue as Revuforj and Niktimvo ramp - Stock Titan
Syndax Pharmaceuticals | 8-K: Syndax Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Syndax (NASDAQ: SNDX) posts 224% Q1 revenue surge and lower loss - Stock Titan
Vanguard Capital Management holds 4.46M shares in Syndax (SNDX) - Stock Titan
Syndax Pharmaceuticals earnings face test as competition heats up By Investing.com - Investing.com India
Syndax Pharmaceuticals earnings face test as competition heats up - Investing.com UK
Syndax Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Syndax Pharmaceuticals Q4 2025 earnings preview - MSN
SNDX Stock Price, Quote & Chart | SYNDAX PHARMACEUTICALS INC (NASDAQ:SNDX) - ChartMill
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):